[HTML][HTML] Current treatments for non-small cell lung cancer
Q Guo, L Liu, Z Chen, Y Fan, Y Zhou, Z Yuan… - Frontiers in …, 2022 - frontiersin.org
Despite improved methods of diagnosis and the development of different treatments,
mortality from lung cancer remains surprisingly high. Non-small cell lung cancer (NSCLC) …
mortality from lung cancer remains surprisingly high. Non-small cell lung cancer (NSCLC) …
[HTML][HTML] The efficacy of ginsenoside Rg3 combined with first-line chemotherapy in the treatment of advanced non-small cell lung cancer in China: a systematic review …
Z Peng, WW Wu, P Yi - Frontiers in Pharmacology, 2021 - frontiersin.org
Background: For advanced non-small cell lung cancer (NSCLC) patients, first-line
chemotherapy is the main treatment in the clinic despite its efficacy is limited and adverse …
chemotherapy is the main treatment in the clinic despite its efficacy is limited and adverse …
Self-targeted polymersomal co-formulation of doxorubicin, camptothecin and FOXM1 aptamer for efficient treatment of non-small cell lung cancer
In spite of huge developments in cancer treatment, versatile combinational formulations of
different chemotherapeutic agents to enhance anticancer activity while reducing systemic …
different chemotherapeutic agents to enhance anticancer activity while reducing systemic …
[HTML][HTML] Circ_0072083 interference enhances growth-inhibiting effects of cisplatin in non-small-cell lung cancer cells via miR-545-3p/CBLL1 axis
H Li, F Liu, W Qin - Cancer cell international, 2020 - Springer
Background Non-small-cell lung cancer (NSCLC) is one of the common cancers in the
world. Circular RNA 0072083 (circ_0072083, circZFR) has been reported to be associated …
world. Circular RNA 0072083 (circ_0072083, circZFR) has been reported to be associated …
[HTML][HTML] Multidisciplinary team discussion results in survival benefit for patients with stage III non-small-cell lung cancer
HY Hung, YH Tseng, HS Chao, CH Chiu, WH Hsu… - PLoS …, 2020 - journals.plos.org
Background The treatment for stage III non-small cell lung cancer (NSCLC) often involves
multi-modality treatment. This retrospective study aimed to evaluate whether …
multi-modality treatment. This retrospective study aimed to evaluate whether …
[HTML][HTML] Circ_ZFR contributes to the paclitaxel resistance and progression of non-small cell lung cancer by upregulating KPNA4 through sponging miR-195-5p
J Li, R Fan, H Xiao - Cancer cell international, 2021 - Springer
Background A growing body of evidence has demonstrated the vital roles of circular RNAs
(circRNAs) in cancer progression and drug resistance. We intended to explore the roles and …
(circRNAs) in cancer progression and drug resistance. We intended to explore the roles and …
Circular RNA ZFR accelerates non-small cell lung cancer progression by acting as a miR-101-3p sponge to enhance CUL4B expression
H Zhang, X Wang, B Hu, F Zhang… - Artificial cells …, 2019 - Taylor & Francis
Background Non-small-cell lung carcinoma (NSCLC) is the most common type of lung
cancer. Circular RNA ZFR (circZFR) is an identified circular RNA (circRNA) that is correlated …
cancer. Circular RNA ZFR (circZFR) is an identified circular RNA (circRNA) that is correlated …
[HTML][HTML] Multidisciplinary consensus statement on the clinical management of patients with stage III non-small cell lung cancer
M Majem, J Hernández-Hernández… - Clinical and …, 2020 - Springer
Stage III non-small cell lung cancer (NSCLC) is a very heterogeneous disease that
encompasses patients with resected, potentially resectable and unresectable tumours. To …
encompasses patients with resected, potentially resectable and unresectable tumours. To …
[HTML][HTML] Hesperetin reverses P‑glycoprotein‑mediated cisplatin resistance in DDP‑resistant human lung cancer cells via modulation of the nuclear factor‑κB signaling …
W Kong, X Ling, Y Chen, X Wu… - International …, 2020 - spandidos-publications.com
Lung cancer is the leading cause of cancer‑associated mortality worldwide. Cisplatin (DDP)
is a first‑line chemotherapeutic drug for the treatment of lung cancer; however, the majority of …
is a first‑line chemotherapeutic drug for the treatment of lung cancer; however, the majority of …
Real-world effectiveness and prognostic factors analysis of stages I–III non-small cell lung cancer following neoadjuvant chemo-immunotherapy or neoadjuvant …
Z Liu, Z Gao, M Zhang, X Wang, J Gong… - Annals of Thoracic and …, 2022 - jstage.jst.go.jp
Purpose: Immune checkpoint inhibitors (ICIs) have been successfully used in many clinical
trials related to immunotherapy. This study aimed to investigate the clinical efficacy of ICIs …
trials related to immunotherapy. This study aimed to investigate the clinical efficacy of ICIs …